I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Diabetes prevalence in Morocco is estimated to be 6.4%.\[[@ref1]\] Fear of hypoglycaemia and gain in body weight are barriers for initiation of insulin therapy.\[[@ref2]\] Modern insulin analogues are a convenient new approach or tool to glycaemic control, associated with low number of hypoglycaemia and favourable weight change.\[[@ref3]\] A~1~chieve, a multinational, 24-week, non-interventional study, assessed the safety and effectiveness of insulin analogues in people with T2DM (*n* = 66,726) in routine clinical care.\[[@ref4]\] This short communication presents the results for patients enrolled from Agadir, Morocco.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Please refer to editorial titled: The A~1~chieve study: Mapping the Ibn Battuta trail.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

A total of 201 patients were enrolled in the study. The patient characteristics for the entire cohort divided as insulin-naïve and insulin users is shown in the [Table 1](#T1){ref-type="table"}. Glycaemic control at baseline was poor in this population. The majority of patients (48.8%) started on or were switched to biphasic insulin aspart. Other groups were insulin detemir (*n* = 54), insulin aspart (*n* = 8), basal insulin plus insulin aspart (*n* = 8) and other insulin combinations (*n* = 33).

###### 

Overall demographic data

![](IJEM-17-399-g001)

After 24 weeks of treatment, overall hypoglycaemia reduced from 20.8 events/patient-year to 4.3 events/patient-year in insulin user group whereas hypoglycaemic events increased from 0.3 events/patient-year to 2.0 events/patient-year in insulin naïve group. However, this hypoglycaemia incidence in insulin naive group at 24 weeks was still lower than that observed in insulin users at baseline. Major hypoglycaemic events did not occur in any of the study patients. SADRs were reported in 1.5% of insulin users. Blood pressure and lipid profile improved in the total cohort, but the findings were limited by number of observations. Quality of life also improved after 24 weeks of treatment \[Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}\].

###### 

Overall safety data
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###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in the total cohort \[[Table 4](#T4){ref-type="table"}\].

###### 

Overall efficacy data
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Biphasic insulin aspart ± OGLD {#sec2-1}
------------------------------

Of the total cohort, 98 patients started on biphasic insulin aspart ± OGLD, of which 69 (70.4%) were insulin naïve and 29 (29.6%) were insulin users. After 24 weeks of treatment, hypoglycaemic events reduced from 21.5 events/patient-year to 1.2 events/patient-year in insulin user group whereas hypoglycaemia increased from 0.4 events/patient-year to 2.4 events/patient-year in insulin naïve group. Quality of life also improved at the end of the study \[Tables [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin naïve and insulin user groups \[[Table 7](#T7){ref-type="table"}\].

###### 

Biphasic insulin aspart±oral glucose-lowering drug efficacy data
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Basal + insulin aspart ± OGLD {#sec2-2}
-----------------------------

Of the total cohort, 8 patients started on basal + insulin aspart ± OGLD, of which 1 (12.5%) was insulin naïve and 7 (87.5%) were insulin users. After 24 weeks, hypoglycaemic events reduced from 26.0 events/patient-year to 9.3 events/patient-year in insulin user group \[Tables [8](#T8){ref-type="table"} and [9](#T9){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug safety data

![](IJEM-17-399-g008)

###### 

Insulin dose

![](IJEM-17-399-g009)

All parameters of glycaemic control improved from baseline to study end in those who started on or were basal + insulin aspart ± OGLDs for insulin-user group \[[Table 10](#T10){ref-type="table"}\].

###### 

Basal+insulin aspart±oral glucose-lowering drug efficacy data

![](IJEM-17-399-g010)

Insulin detemir ± OGLD {#sec2-3}
----------------------

Of the total cohort, 54 patients started on insulin detemir ± OGLD, of which 46 (85.2%) were insulin naïve and 8 (14.8%) were insulin users. After 24 weeks of starting or switching to insulin detemir, hypoglycaemia reduced from 11.4 events/patient-year to 0.0 events/patient-year in insulin user group whereas hypoglycaemic events increased from 0.0 to 1.1 events/patient-year in insulin naïve group. An improvement in quality of life was also observed at the end of the study \[Tables [11](#T11){ref-type="table"} and [12](#T12){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug safety data

![](IJEM-17-399-g011)

###### 

Insulin dose
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All parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir ± OGLDs for insulin-naïve group whereas mean HbA~1~c and FPG values improved for insulin user group \[[Table 13](#T13){ref-type="table"}\].

###### 

Insulin detemir±oral glucose-lowering drug efficacy data

![](IJEM-17-399-g013)

Insulin aspart ± OGLD {#sec2-4}
---------------------

Of the total cohort, 8 patients started on insulin aspart ± OGLD, of which 5 (62.5%) were insulin naïve and 3 (37.5%) were insulin users. After 24 weeks of treatment, hypoglycaemic events reduced from 65.0 events/patient-year to 6.5 events/patient-year in insulin user group \[[Table 14](#T14){ref-type="table"}\]. Quality of life improved in both the groups.

###### 

Insulin aspart±oral glucose-lowering drug safety data
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###### 

Insulin dose
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Mean FPG values improved from baseline to study end in those who started on or were switched to insulin aspart ± OGLDs for insulin-naïve group \[[Table 16](#T16){ref-type="table"}\].

###### 

Insulin aspart±oral glucose-lowering drug efficacy data

![](IJEM-17-399-g016)

C[ONCLUSION]{.smallcaps} {#sec1-4}
========================

Our study reports improved glycaemic control following 24 weeks of treatment with any of the insulin analogues (Biphasic insulin aspart; Basal + insulin aspart; insulin detemir; insulin aspart) with or without OGLD. Quality of life improved in the total cohort. Major hypoglycaemic episodes were null at 24 weeks. SADRs were reported in 1.5% of insulin users. Overall, body weight increased in insulin naïve population and decreased in insulin users. Though the findings are limited by number of patients, still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating Type 2 diabetes in in Agadir, Morocco.
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